Individualized quality of life, standardized quality of life, and distress in patients undergoing a phase I trial of the novel therapeutic Reolysin (reovirus)

被引：22

作者：

Carlson L.E. ^{[1
,2
,3
]}

Bultz B.D. ^{[1
,2
,4
]}

Morris D.G. ^{[2
,5
]}

机构：

[1] Department of Psychosocial Resources, Tom Baker Cancer Centre, Calgary, Alta.

[2] Department of Oncology, University of Calgary, Calgary, Alta.

[3] Department of Psychology, University of Calgary, Calgary, Alta.

[4] Department of Psychiatry, University of Calgary, Calgary, Alta.

[5] Department of Medicine, University of Calgary, Calgary, Alta.

来源：

Health and Quality of Life Outcomes | / 3卷 / 1期

关键词：

Advanced cancer; Depression; Phase I trials; Quality of life; Spirituality;

D O I：

10.1186/1477-7525-3-7

中图分类号：

学科分类号：

摘要：

Background: The purpose of this study was to evaluate the individualized and standardized quality of life (QL) and psychological distress of patients participating in a Phase I trial of the novel therapeutic reovirus (Reolysin). Methods: 16 patients with incurable metastatic cancer were interviewed prior to being accepted into the phase I trial with a semi-structured expectations interview, the Schedule for the Evaluation of Individual Quality of Life - Direct Weighting (SEIQoL-DW), the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), the Brief Symptom Inventory (BSI), the Beck Depression Inventory (BDI), and the Spiritual Health Inventory (SHI). Results: Patients were able to complete all measures. They felt hopeful and excited about the trial, with about two thirds hoping for disease regression and one third hoping for a cure. The most commonly spontaneously nominated areas of QL were family relationships, activities and friends, and the overall SEIQoL mean index score was 69. Health was nominated by only 38% of the sample. Scores on the SEIQoL were correlated with global QL on the EORTC QLQ C-30. Scores on the BDI and BSI were lower than reported for similar populations, and on the SHI scores were similar to other samples. Global QL on the EORTC QLQ C-30 and depression scores were associated with time to death in the nine patients who had died at the time of writing. Conclusions: Individualized QL is easy to assess in seriously ill cancer patients, provides useful information relative to each individual, and is related to standard QL measures. Repeated Assessment of individualized QL of patients in Phase I trials would be a useful addition to the research. © 2005 Carlson et al; licensee BioMed Central Ltd.

引用

页数：11

共 36 条

[1]

Feld R., Endpoints in cancer clinical trials: Is there a need for measuring quality of life?, Supportive Care in Cancer, 3, pp. 23-27, (1995)

[2]

Morris J., Perez D., McNoe B., The use of quality of life data in clinical practice, Quality of Life Research, 7, pp. 85-91, (1998)

[3]

Kiebert G.M., Curran D., Aaronson N.K., Quality of life as an endpoint in EORTC clinical trials, Statistics in Medicine, 17, pp. 561-569, (1998)

[4]

Spilker B., Quality of Life Assessments in Clinical Trials, (1990)

[5]

Taylor K., Macdonald K., Bezjak A., Ng P., Depetrillo A.D., Physicians' perspective on quality of life: An exploratory study of oncologists, Quality of Life Research, 5, pp. 5-14, (1996)

[6]

Gough I., Dalgleish L., What value is given to quality of life assessment by health professionals considering response to palliative chemotherapy for advanced cancer?, Cancer, 68, pp. 220-225, (1991)

[7]

Schwarz R., Bernhard J., Flechtner H., Hurny C., Kuchler T., Guidelines for the assessment of quality of life in oncology - Implementing adequate methods and their content, Journal of Cancer Research and Clinical Oncology, 120, pp. 691-692, (1994)

[8]

Melink T.J., Clark G.M., Von Hoff D.D., The impact of phase I clinical trials on the quality of life of patients with cancer, Anticancer Drugs, 3, pp. 571-576, (1992)

[9]

Hutchison C., Phase I trials in cancer patients: Participants' perceptions, Eur. J. Cancer Care (Engl.), 7, pp. 15-22, (1998)

[10]

Cheng J.D., Hitt J., Koczwara B., Schulman K.A., Burnett C.B., Gaskin D.J., Rowland J.H., Meropol N.J., Impact of quality of life on patient expectations regarding phase I clinical trials, J. Clin. Oncol., 18, pp. 421-428, (2000)

← 1 2 3 4 →